- Home
- AKTX vs BNR Comparison
AKTX vs BNR Comparison
Compare AKTX & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- BNR
- Stock Information
- Founded
- AKTX N/A
- BNR 2014
- Country
- AKTX United States
- BNR China
- Employees
- AKTX N/A
- BNR N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- BNR Medical Specialities
- Sector
- AKTX Health Care
- BNR Health Care
- Exchange
- AKTX Nasdaq
- BNR Nasdaq
- Market Cap
- AKTX 29.1M
- BNR 29.1M
- IPO Year
- AKTX N/A
- BNR 2020
- Fundamental
- Price
- AKTX $1.35
- BNR $2.61
- Analyst Decision
- AKTX
- BNR
- Analyst Count
- AKTX 0
- BNR 0
- Target Price
- AKTX N/A
- BNR N/A
- AVG Volume (30 Days)
- AKTX 32.7K
- BNR 55.0K
- Earning Date
- AKTX 05-19-2025
- BNR 05-28-2025
- Dividend Yield
- AKTX N/A
- BNR N/A
- EPS Growth
- AKTX N/A
- BNR N/A
- EPS
- AKTX N/A
- BNR N/A
- Revenue
- AKTX N/A
- BNR $70,669,261.00
- Revenue This Year
- AKTX N/A
- BNR $136.32
- Revenue Next Year
- AKTX N/A
- BNR N/A
- P/E Ratio
- AKTX N/A
- BNR N/A
- Revenue Growth
- AKTX N/A
- BNR N/A
- 52 Week Low
- AKTX $0.85
- BNR $2.18
- 52 Week High
- AKTX $4.40
- BNR $8.99
- Technical
- Relative Strength Index (RSI)
- AKTX 52.00
- BNR 36.21
- Support Level
- AKTX $1.18
- BNR $2.30
- Resistance Level
- AKTX $1.42
- BNR $2.78
- Average True Range (ATR)
- AKTX 0.10
- BNR 0.28
- MACD
- AKTX -0.01
- BNR 0.07
- Stochastic Oscillator
- AKTX 56.67
- BNR 43.00
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.